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CObjective: To analyze the cost-effectiveness of a meningococcal C vac-
cination program in Brazil. Methods: A hypothetical cohort of
3,194,038 children born in Brazil in 2006 was followed for 10 years. A
decision tree model was developed using the TreeAge Pro 2007 soft-
ware program to compare universal infant vaccination with the cur-
rent program. Epidemiological and cost estimates were based on data
retrieved from National Health Information Systems and the literature.
The analysis was conducted from the public health care system and
societal perspectives. Costs are expressed in 2006 Brazilian reals (R$).
Results: At 94% coverage, the program would avoid 1,218 cases, 210
deaths, and 14,473 life-years lost, a reduction of, respectively, 45%, 44%,
and 44%, for the 10-year period. Vaccination costs of R$320.9 million
would not be offset by R$4 to R$7.9 million decreases in disease treat- O
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doi:10.1016/j.jval.2011.05.045ent costs. A national vaccination program would cost R$21,620 per
ife-year saved from the perspective of the health-care system and
$21,896 per life-year saved from society’s perspective. Results were
ost sensitive to case fatality rate, disease incidence, and vaccine cost.
onclusions: A universal childhood vaccination program against me-
ingococcal C proved to be a cost-effective strategy, supporting the
ecent decision of the Brazilian government. These results could con-
ribute to defining the most favorable price of the vaccine and to mon-
toring its impact on the population.
eywords: Brazil, childhood, cost-effectiveness analysis, meningococ-
al C conjugate vaccine, vaccination program.
opyright © 2011, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Meningococcal disease (MD) is a major health problem worldwide.
In Brazil, MD is endemic, with occasional circumscribed out-
breaks. Four major epidemics occurred in the 20th century, the
last one was a serogroup B epidemic that lasted from the late 1980s
to the early 2000s [1,2]. In recent years, MD incidence rates have
returned to the historical endemic threshold of around 2 cases per
100,000 inhabitants. Children younger than 5 years of age are the
most affected age group, with the highest incidence rates in the
first year of life [3,4]. In the past decade, a progressive increase in
the proportion of cases caused by serogroup C has been observed
in the country [4,5]. In 2008, approximately 68% of MD cases were
due to serogroup C. Early initiation of antibiotic therapy and clin-
ical management in intensive care environment allowed for a re-
duction in mortality related to MD; however, the disease still has a
high case fatality rate and risk of serious sequelae, particularly in
developing countries [1,6]. Vaccination is considered the best pre-
vention and control strategy for MD [7].
Meningococcal C conjugate (MenCC) and meningococcal A C
olysaccharide vaccines are available at the Brazilian public
ealth-care system for outbreak control and immunization of in-
ividuals at high risk of invasive disease caused by Neisseria men-
* Address correspondence to: Patrícia Coelho de Soárez, Departam
de São Paulo. Av. Dr. Arnaldo, 455 – 2° andar Cerqueira César, São
E-mail: pcsoarez@uol.com.br.
1098-3015/$36.00 – see front matter Copyright © 2011, Internation
Published by Elsevier Inc.ngitides [8]. The vaccines are also available through the private
ealth-care system, with low population coverage. This strategy
esulted in very low vaccine coverage; less than 5% of children
ounger than 5 years of age received at least one dose of MenCC in
009. In September 2010, MenCC was introduced into the routine
mmunization schedule of infants (three doses at 3, 5, and 12
onths) with catch-up vaccination for children younger than 2
ears of age.
The objective of this economic evaluation was to analyze the
ost-effectiveness of a MenCC universal vaccination program for
hildren younger than 1 year of age in Brazil.
Methods
Model design
A deterministic decision tree model for cost-effectiveness analysis
was developed (TreeAge Pro 2007 software program, TreeAge Soft-
ware Inc., Williamstown, MA) to compare universal infant MenCC
vaccination to the alternative strategy of vaccinating only high-
risk individuals (Fig. 1). A hypothetical cohort of 3,194,038 children
born in Brazil in 2006 was studied for a 10-year period after the
introduction of a routine MenCC vaccination program.
de Medicina Preventiva, Faculdade de Medicina da Universidade
o 01246-903, Brasil.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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MD and the proportion of cases caused by serogroup C in the past
decade without considering the possibility of an epidemic. The
10-year period was chosen primarily because around 62% of cases
of MD occur in children younger than 10 years of age but also
because of the uncertain behavior of the MD epidemiology. Be-
cause epidemics and the causal serogroup are difficult to predict, a
static model with a very long time horizon could deviate too much
from a scenario that would probably include outbreaks.
The analysis compared two strategies: universal infant vacci-
nation with MenCC and an alternative strategy of vaccination of a
high-risk population. According to the diagram of the model (Fig.
1), the universal vaccination strategy considers two alternatives:
vaccinated and nonvaccinated individuals, depending on vaccina-
tion coverage. In the vaccinated arm, the vaccine may protect or
not. Protection depends on vaccine effectiveness and the propor-
tion of disease caused by serogroup C and was considered to re-
main stable in the first 2 years after vaccination. In the third year,
a proportion of children will lose protection. Those who continue
to be protected at the third year will remain so (no meningococcal
disease) until the end of the analyzed period. In those who lose
protection in the third year, MD may or may not develop (clone 1)
and may progress to cure or death. The survivors may or may not
have sequelae. Those in whom MD did not develop in the third
year may remain disease free or MD may develop in the fourth
year by repeating the outcomes described, and so on until the
10th year. MD may or may not develop in children unprotected
in the first year after vaccination. In those who finish the year
without MD, there is a chance that the disease will develop in the
next year. The same chain of events repeats until the 10th year
(represented in the clone 2).
In the nonvaccinated arm of the universal vaccination strategy,
the starting event will be the same as that described for the group of
unprotected children in the first year of vaccination (clone 2).
In the alternative strategy, children follow the same flow of
events described in the nonvaccinated arm of the universal vacci-
nation strategy (clone 2).
This model estimates the burden of disease caused by all me-
Fig. 1 – Simplified diagram of the decision tree model used t
vaccination program in children younger than 1 year in Brazningococcal serogroups and calculates the number of cases of se-rogroup C disease avoided by the vaccine. Under universal vacci-
nation, MD patients have the same outcomes as those in the
alternative strategy, but in different proportions, depending on
vaccination coverage, vaccine effectiveness, and proportion of MD
caused by serogroup C. Herd protection conferred by the vaccine
was not considered in the model.
The economic analysis was performed from the perspective of
both the public health-care system (Sistema Único de Saúde) and
society. The public health-care system perspective included the
direct medical costs (medical visits, hospital admissions, labora-
tory tests, and imaging studies, and medications). The societal
perspective included direct medical costs, direct nonmedical costs
(transportation to health services), and the indirect costs related to
caregiver work loss. Costs were estimated in Brazilian reals at 2006
prices (US$1.00  R$2.098). Future costs and consequences were
discounted at 5% per year, as recommended [9]. Univariate and
multivariate sensitivity analyses were performed for selected vari-
ables, and ranges of variation were determined by the literature
and the authors’ assumptions. Best and worst case scenario anal-
yses were conducted. The worst case scenario assumed the lowest
rates of vaccine protection in the first and second years, the lowest
MD incidence and case fatality rates, and a 50% higher vaccine
price (R$48.64 per dose). The best case scenario assumed the high-
est rates of vaccine protection in the first and second years, the
highest MD incidence and case fatality rates, and a 50% lower
vaccine price (R$16.22 per dose). Other parameter estimates re-
mained the same as the base case. A probability sensitivity anal-
ysis (PSA) was conducted. The purpose of a PSA is to explore the
implications of parameter uncertainty for the results of cost-effec-
tiveness analyses [10]. The uncertainty surrounding important pa-
rameters such as vaccine protection in the first and second years
(vaccine effectiveness percentage of MD due to serogroup C), MD
incidence, and case fatality rates and cost per vaccine dose was
explored using Monte Carlo simulation (1000 interactions), which
randomly chooses values from the parameter distributions to
jointly estimate costs and effects of each strategy. In this analysis,
uniform distributions were applied to serogroup coverage (per-
centage of MD due to serogroup C), MD incidence, case fatality
alyze the cost-effectiveness of a meningococcal C universalo an
il.rate, vaccine dose cost, and log normal for vaccine effectiveness,
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nd maximum values used to estimate the parameters for the
istributions are reported in Table 1. The results of the PSA are
resented as the confidence interval for the incremental cost-ef-
ectiveness ratio (ICER) and as cost-effectiveness acceptability
urves.
Vaccination strategy
In the universal vaccination strategy, the infants will receive three
doses of MenCC (two doses in the first semester of life and a
booster dose in the second year). It was assumed that the vaccine
would be administered simultaneously with other vaccines that
are part of the Brazilian infant immunization schedule.
The MenCC vaccination coverage rate was assumed to be 94%
based on data from a recent household survey that estimated vac-
cination coverage with three doses of DTP-Hib vaccine (recom-
mended at 2, 4, and 6 months of life) of 94% [12]. It was assumed
that vaccination coverage will be constant in the entire period of
analysis. Based on administrative data for doses administered in
2006, MMR (measles, mumps, rubella) vaccine coverage is 95%.
So, it was also assumed that all children initiating vaccination will
receive the complete three-dose schedule. Based on published
data, vaccine effectiveness against serogroup C was estimated to
be 95% in the first 2 years post-vaccination, with a 10% loss in
vaccine-induced protection in the third year, and remaining stable
thereafter [13–17]. Adverse events post-MenCC vaccines are rare
and usually mild and were not taken into account in this analysis
[16]. Catch-up vaccination of susceptible older children was also
not considered.
It was assumed that all vaccinations would be carried out
through the public health-care system. Vaccine price was as-
sumed to be R$32.43 per dose, paid by the Brazilian National Im-
munization Program (NIP) in 2006. In the absence of national data,
administration cost per dose was assumed to be R$2.098 (US$1.00),
following methodology used in a previous study [18]. The vaccine
wastage rate was set at 5% considering a single-dose package, as
recommended by World Health Organization (WHO) when esti-
mating the number of needed doses to introduce a new vaccine
into an NIP [19].
Epidemiological data
The MD incidence rates were estimated based on the number of
confirmed cases of disease reported to the Notifiable Diseases In-
formation System (Sistema de Informação de Agravos de Notifica-
ção [SINAN]) in 2006. The SINAN database contains national data
on frequency and outcomes (cure or death) of MD, according to age
group and clinical syndromes (meningitis, meningococcemia, or
meningitis with meningococcemia) [20].
In Brazil, the pathogen is not identified in a large proportion
of bacterial meningitis (BM). In São Paulo state, with better
health-care coverage, most (58%) episodes of BM in children
younger than 10 years of age were reported to SINAN as “un-
specified BM” in 2006. N. meningitidis was responsible for 36.3%
of BM with the identified causative microorganism in this age
group [21]. Assuming that 1) the proportion of cases of BM with
identified pathogens in other states would be similar to that in
São Paulo and 2) the proportion of meningococcal meningitis
among cases of unspecified BM would be similar to the observed
in cases of BM with an identified pathogen, we estimated the
numbers of episodes of meningococcal meningitis reported un-
der the diagnosis of unspecified BM. These numbers were added
to the confirmed cases of MD to obtain the estimate for the total
numbers of MD.
Age-specific incidence rates were calculated using popula-
tion estimates for Brazil in 2006, based on the 2000 Brazilian
Census, for age groups younger than 1 year, 1 to 4 years, and 5 to w9 years (Table 1) [22]. Case-fatality rates by age groups were
calculated based on confirmed cases and deaths reported to
SINAN (Table 1). Life-years lost were calculated by subtracting
the age at which the death would occur from the age group–
specific life expectancy in Brazil.
It was assumed that survivors of MD could have skin necrosis,
amputation, neurological sequelae, deafness, or no sequelae. Se-
quelae rates were assumed by the authors based on those in the
literature (Table 1) [23–26].
National data from SIREVA II (Network Surveillance System for
the Bacterial Agents Responsible for Pneumonia and Meningitis)
was used to determine the proportion of MD caused by serogroup
C in Brazil (Table 1) [5].
Cost data
It was assumed that all patients were hospitalized and that each
patient would require one emergency department visit before
hospital admission and one follow-up visit after discharge. The
proportions of hospital admissions through the public (77%) and
private (23%) health-care systems were taken from a 2003 na-
tional household survey (Pesquisa Nacional por Amostra de Do-
micílios) [27].
Costs for hospital admissions in the public sector were ob-
tained from the Hospital Information System (Sistema de Infor-
mação Hospitalar) [28]. The private sector hospitalization costs
were obtained from the Tabela Única Nacional de Equivalência de
Procedimentos, TUNEP), a reference table used by the National
Health Agency (Agência Nacional de Saúde) for the reimburse-
ment of procedures performed by the Sistema Único de Saúde
(SUS) for the private prepaid health plans clients [29]. Costs for
ambulatory treatments were obtained from the Ambulatory Infor-
mation System (Sistema de Informação Ambulatorial) and the
TUNEP [29,30].
Based on data from the state of São Paulo SINAN database, it
was assumed that each MD case would lead to chemoprophylaxis
for 10 close contacts of the patient. This assumption was also
present in other studies of economic evaluation [31,32]. It was
assumed that all contacts would receive rifampicin and the adult
dose (8 capsules of 300 mg per person) was used to estimate its
costs. The estimated cost of chemoprophylaxis per MD case was
R$15.20 (R$0.19  8 capsules  10 contacts).
Children with sequelae incurred sequelae-specific proce-
ure costs in addition to costs related to acute MD. The esti-
ated costs of neurological sequelae were based on annual ref-
rence costs of care for children with encephalopathy in a
pecialized institution.
Treatment costs for deafness were not included because no
ational data exist as a basis for reasonable estimates of the costs
f diagnosis and treatment of deafness in the Brazilian population
n general, not in children or in children who have deafness as a
equela of meningococcal meningitis.
Nonmedical direct costs were included in the analysis from
he societal perspective. Transportation costs were calculated
ased on unit cost of the average cost of public transportation in
razil in 2006 (R$1.89) and the number of visits needed during
reatment.
The Human Capital Method was adopted to estimate indirect
osts, included in the analysis from the perspective of society. In
his study, indirect costs represent the work time lost by mothers
f children acutely ill with MD or with neurological sequelae. The
nalysis followed children from 0 to 10 years old and added the
osts of lost productivity by parents caring for their children with
equelae until 10 years of age. Costs of lost productivity of patients
ith sequelae in adulthood were not included.
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Parameters Base case Sensitivity
analysis
Distribution type Source
Vaccine*
Vaccination coverage 0.94 0.85 [12]
Vaccine effectiveness
(first 2 y)
0.95 0.80–0.95 Log normal
(SD  0.0375)
[11,13–17]
Waning immunity (in
the third year)
0.10 0.10–0.20 [16,17]
Wastage rate, % 5 5
Epidemiological
MD incidence rates
(all serogroups)
1 y 0.0002282 0.000151–0.000553 Uniform 0.0001512–
0.000553
Authors’ assumption based
on SINAN [11]
1–4 y 0.0000927 0.00006388–0.000215 Uniform 0.00006388–
0.000215
5–9 y 0.0000511 0.0000323–0.000083 Uniform 0.0000323–
0.000083
% of MD due to
serogroup C
case fatality
rates
0.533 0.20–0.80 Uniform 0.20–0.80 [5,11]
1 y 0.1933 0.10–0.30 Uniform 0.10–0.30 Authors’ assumption based
on SINAN [11]
1–4 y 0.1857 0.10–0.30 Uniform 0.10–0.30
5–9 y 0.1389 0.05–0.20 Uniform 0.05–0.20
Skin necrosis (1–9 y) 0.08 [23]
Amputation (1–9 y) 0.03 [23]
Neurological
sequelae (1–9 y)
0.05 [23]
Deafness (1–9 y) 0.05
Health-care system
perspective
Society
perspective
Health-care costs†
Vaccine dose 32.43 32.43 50% to 50% CGPNI
Vaccine
administration
costs
2.098 2.098 [18]
Hospital treatment‡ [28,30]
1 y 1,203.19 1,519.31 75% to 75%
1 y 1,078.83 1,340.61 75% to 75%
2 y 1,072.59 1,329.21 75% to 75%
3–4 y 1,043.98 1,323.82 75% to 75%
5–9 y 1,016.26 1,278.04 75% to 75%
Sequelae treatment
Skin necrosis
(1–9 y)
406.04 406.04 [29]
Amputation (1–9 y) 327.34 327.34 [29]
Neurological
sequelae (1–9 y)
8,052.96 19,154.40§ 50% to 50% AACD
Deafness (1–9 y) 0.00 0.00
Discount rate 0 0 5% to 10% Ministerio da Saude, 2009
AACD, Disabled Child Assistance Association (Associação de Assistência à Criança Deficiente); CGPNI, Coordenação Geral do Programa Nacional
de Imunizações; SINAN, Brazilian Notifiable Diseases Information System.
* Adverse events associated with vaccination were not taken into account in this analysis.
† Costs in 2006 reals (R$).
‡ Hospital treatment costs include hospitalization, two medical visits (pre- and post-hospitalization), and chemoprophylaxis for close contacts
in the health-care system perspective. In the society perspective, they also include transport (case and family) and caregiver productivity
losses.
§ From the perspective of society, the annual treatment of neurological sequelae includes sequelae treatment (R$8,052.96) and productivity loss
of parents (R$11,101.44), the base case showed the value of R$19,154.40. The low value was R$9,577.20 (50%) and high value was R$28,731.60
(50%). In the perspective of the health-care system, the annual treatment of neurological sequelae includes only the treatment of sequelae.The base case showed the value of R$8,052.96, the low value was R$4,026.48 (50%) and high value was R$12,079.44 (50%).
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Disease burden and costs of MD
The model estimated that with the alternative strategy (vaccination
of high-risk persons), 2,728 children of the 2006 birth cohort would
acquire MD and 474 of them would die in the 10-year period. These
cases would result in R$23 million in total costs, including
R$18,386,760 in treatment costs and R$4,698,445 in vaccination costs
(Table 2).
The universal MenCC vaccination program, at 94% coverage,
would prevent 1,218 cases and 210 deaths, allowing a gain of
14,473 life-years, a reduction in disease outcomes of, respectively,
45%, 44%, and 44% for the 10-year period. Universal vaccination of
infants would cost R$320 million more than the alternative strat-
egy, with a R$7.9 million reduction in disease treatment costs,
resulting in ICERs of R$256,903 per case avoided and R$21,620 per
life-year saved (LYS) from the perspective of society. From the
perspective of the health-care system, universal vaccination
would result in ICERs of R$260,182 per case avoided and R$21,896
per LYS (Table 2). When a discount rate of 5% per year was applied
for both health and monetary effects, the ICERs were R$24,804 and
R$25,088 per LYS, respectively, from the society and health-care
system perspectives.
Sensitivity analysis
In a deterministic one-way sensitivity analysis, nine key parame-
ters were varied. The ICERs were most sensitive to variations in
vaccine protection in the first and second years followed by case
fatality rates, disease incidence rates, and cost per vaccine dose
(Fig. 2). When the lowest percentage of MD due to serogroup C
Table 2 – Expected cumulative effects of a universal childh
after 10 years of program implementation in Brazil.
Parameter Alternative strategy*
Disease impact
Total no. of cases 2,728
Total no. of deaths 474
Total no. of life-years lost 32,778
Health-care costs†
Intervention cost‡ 4,698,445
Disease treatment costs in the
society perspective§
18,386,760
Disease treatment costs in the
health-care system perspective
9,178,191
Society§
(undiscounted)
ICERs
Cost per case avoided 256,903
Cost per death avoided 1,490,038
Cost per LYS avoided 21,620
ICERs, incremental cost-effectiveness ratios; LYS, life-year saved.
* Alternative strategy, vaccination of children at high risk of disease
† In 2006 reals (R$).
‡ The alternative strategy includes doses of vaccine delivered to chi
Program in 2006. The universal vaccination strategy includes three
vaccination would receive the complete three-dose schedule.
§ Disease treatment costs in the society perspective include direct m
pre- and post-hospitalization, diagnostic tests, and medication), fam
 Disease treatment costs in the health-care system perspective inc
two medical visits pre- and post-hospitalization, diagnostic tests, a
¶ Discounted 5% per year.(0.20) was used to calculate the vaccine protection in the first andsecond years (vaccine effectiveness  percentage of MD due to
serogroup C), incremental cost per LYS increased by 222% (to
R$69,622). When case fatality rates of all age groups were de-
creased simultaneously to the lowest estimates, the incremental
cost per LYS increased by 103% (to R$44,024). With the lowest MD
incidence rates in the past 10 years, there was an approximate
increase of 51% in the ICER, and with the highest rates, there was
an approximate decrease of 56% in the ICER.
Increases or decreases in price per vaccine dose had a direct
proportional impact on the ICERs. Figure 3shows the range of val-
ues for ICERs per LYS at different prices per vaccine dose.
Increases in hospital treatment costs and neurological se-
quelae treatment costs did not affect cost-effectiveness ratios.
In the multivariate sensitivity analysis, the ICER varied from
R$1,919 per LYS for the best case scenario to R$313,660 for the worst
case.
The probabilistic sensitivity analysis indicated that the 95%
confidence interval around the ICER (R$21,620 per LYS) was
R$5,704 to R$58,758. The probability that universal infant vaccina-
tion program is cost-effective over a range of willingness-to-pay
values is shown in Figure 4.For a threshold value of approximately
R$38,000 (three gross domestic products [GDPs] per capita per dis-
ability-adjusted life-year [DALY] averted)[33], the probability that
universal infant vaccination program is cost-effective is 87.3%. At
a threshold of approximately R$12,688 (one GDP per capita per
DALY averted) [33], the probability that universal infant vaccina-
tion program is cost-effective is 27.7%.
Discussion
In this study, universal MenCC vaccination for Brazilian infants
immunization with meningococcal C conjugate vaccine
versal vaccination Difference %
1,510 1,218 45
264 210 44
18,305 14,473 44
325,605,312 320,906,867 6,830
10,387,812 7,998,948 44
5,174,489 4,003,702 44
th-care system
discounted)
Society§
(discounted)¶
Health-care system
(discounted)¶
260,182 301,100 304,551
1,509,053 1,723,880 1,743,639
21,896 24,804 25,088
at high risk of disease based on data of the National Immunization
s of vaccine per child. It was assumed that all children who start the
l costs (hospital and ambulatory treatment costs, two medical visits
osts (transport), and the indirect costs (caregiver productivity losses).
only direct medical costs (hospital and ambulatory treatment costs,
edication) and family costs (transport).ood
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capita per DALY saved can be considered cost-effective (2006 Bra-
zilian GDP per capita R$12,688) [33]. Using LYS (which considers
nly mortality) instead of DALY saved (which considers both mor-
ality and morbidity) as an outcome makes this analysis very con-
ervative. The vaccine would be certainly more cost-effective if
isability was taken into account. This result puts the recent de-
ision of the Brazilian government in a favorable perspective, al-
hough ICER threshold values cannot be used as absolute param-
Fig. 2 – Results of a sensitivity analysis according to the para
Table 1. The Word Health Organization threshold value for c
three gross domestic products (GDPs) per capita for each dis
intervention, and interventions costing les than one GDP pe
intervention [32]. The 2006 Brazilian GDP per capita is R$12,
Fig. 3 – The impact of the cost per vaccine dose on the increm
society’s perspective. The Word Health Organization thresh
costing less than three gross domestic products (GDPs) per c
effective intervention, and an intervention costing less than
averted is a very cost-effective intervention [32]. The 2006 Brazilters when economic evaluations are part of policy-making
rocesses [34].
MD causes great fear in the population due to its sudden
nset, rapid progress, high case fatality, and epidemic potential.
he existence of a vaccine to prevent MD generates strong de-
ands from the population and health-care workers for its in-
roduction into the NIPs. These ethical concerns play a key role
n decision making and are not part of a cost-effectiveness anal-
sis [35].
er variation. The values for parameters are presented in
effectiveness suggests that interventions costing less than
ty-adjusted life-year averted is a cost-effective
ita for each DALY averted is a very cost-effective
tal cost-effectiveness ratio per life-year saved from
alue for cost-effectiveness suggests that an intervention
for each disability-adjusted life-year averted is a cost-
GDP per capita for each disability-adjusted life-yearmet
ost-
abili
r cap
688.en
old v
apita
oneian GDP per capita is R$12,688.
1025V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 1 9 – 1 0 2 7During the year 2000, the incidence rates of MD in Brazil were
similar to those observed in developed countries before the intro-
duction of MenCC vaccine into the NIP [14–17,36]. Since 2006, the
year of reference for this study, no significant changes in the inci-
dence and case fatality rates of MD have been observed from a
national perspective. Nevertheless, 20 outbreaks of serogroup C
MD were reported from 2001 to 2009 in Brazil, and the most recent
one, in Bahia state, received much attention in the national media.
The economic evaluation of a prevention technology for MD
has limitations as a tool to support decision making, given that its
methodological assumptions imply the need for predictability of
the disease after the introduction of the vaccine, and epidemics
are, by definition, unanticipated, intense, and frightening events
requiring that public health managers perform specific interven-
tions. The study of the vaccine against MenCC presents a particu-
lar challenge. As the analysis is based on a situation of relative
epidemiology stability of endemic disease, it may lose its rele-
vance very quickly, given the possibility of sudden change in the
epidemiological context.
Although there were available data on the number of MD out-
breaks in Brazil, this study’s costs included only estimates for
MenCC vaccine used to contain these outbreaks (included in the
total vaccine doses per year in the alternative strategy) and che-
moprophylaxis for patients’ contacts because no additional infor-
mation was available for the costs of other public health measures
to control an epidemic, which may be high. Assuming that univer-
sal childhood vaccination is able to avoid epidemics, not including
these costs, biases the results of the analyses against the vaccina-
tion program [35]. Only two economic evaluations of the MenCC
vaccine reported in the literature, however, sought to introduce
epidemic outbreaks in their analysis [32,37].
When estimating epidemiological and cost parameters, this
study optimized the use of existing health information systems,
supplemented with data obtained from careful review of the liter-
ature. Prioritizing national epidemiological data when available
may have contributed to underestimation, and this conservative
perspective was considered in the sensitivity analysis. A correc-
tion strategy was adopted to include a number of episodes of me-
Fig. 4 – Cost-effectiveness acceptaningococcal meningitis estimated to be reported under the diag-nosis unspecified BM, a significant proportion of BM cases
reported to SINAN. In São Paulo state, during the past 5 years, the
proportion of meningococcal meningitis among BM cases in-
creased in parallel with the increase in the proportion of cases
with identification of the causative pathogen, supporting this cor-
rection strategy [38]. Nevertheless, it was not possible to propose a
correction strategy for misdiagnosis and underreporting to SINAN,
despite some evidence pointing to its importance [39].
The measurement of the frequency and intensity of sequelae
was even more difficult, given the lack of national standardized
data. Deafness, in particular, was more underestimated because it
is treated essentially on an outpatient care basis, for which avail-
able administrative data are scarce.
However, approaches to the incorporation of utility weights in
economic evaluations of MD have several limitations, including
lack of country-specific weights for complications and sequelae of
MD and transferability. Most of the published studies used one of
two sources of utility information [31]. Pharmacoeconomic guide-
lines state that utility values obtained from other countries are, in
general, not transferable because of cultural differences [40]. In
Brazil, utility weights are not available, and utilities from other
countries would need to be considered. We analyzed carefully the
data sources and instruments used to collect these data and de-
cided that utility values from the mid-1990s in Canada [31] or de-
veloped by a panel of Dutch physicians [41, 42] would not be trans-
ferable to the Brazilian setting.
An additional complication is the fact that the target popula-
tion (children younger than 10 years old) of our study is unable to
provide utilities with instruments originally developed for adults.
Children are often regarded as unreliable respondents [43], and
the methodology of quality of life measurement in young children
is still in its infancy [42]. Based on these arguments, we preferred
to be conservative and did not include quality of life in our analy-
sis, avoiding the use of a parameter subject to a great deal of un-
certainty and a potential effect on the cost-effectiveness ratio fa-
voring the introduction of MenCC vaccine.
Regarding cost estimates, the cost methodology adopted, the
top-down approach, based on official information of reimburse-
curve for vaccination strategies.bilityment rates, tends to be conservative, but has the advantage of
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other studies. The methodological implications of this decision
were also considered in the sensitivity analysis. Because national
data were not available, the costs of treatment and rehabilitation
of deafness were not included, and these costs may be substantial.
An important limitation is that the lifetime sequelae-specific
medical costs were not included in the analysis. Only the
sequelae-specific procedure costs of the 10-year period of the
nalysis were considered. For neurological sequelae, the cost of
ong-term residential care and special education were not in-
luded. Because deafness treatment was not considered, cochlear
mplant and lifetime costs related to its placement and mainte-
ance were also not accounted for in costs.
The inclusion of indirect costs significantly improves the
hances of demonstrating the cost-effectiveness of the MenCC
accine because indirect costs related to patient productivity
osses may exceed direct medical costs by a factor of 2 when
alculated by the human capital approach [35]. Because our decision
nalysis model followed one birth cohort for 10 years, the indirect
osts included in the analysis were restricted to work time lost by
others due to caregiving and calculated using average salary rates.
ost importantly, the lifetime productivity reduction in survivors
ith sequelae and their caregivers was not included in the analysis
ecause our time horizon was 10 years. This is one of the possible
xplanations for the very similar results of the two perspectives.
Another limitation was the estimate of vaccine administration
osts, for which no Brazilian data are available. Two other vac-
ines were recently introduced into the immunization schedule of
razilian infants: the human monovalent rotavirus vaccine in
006 and the 10-valent pneumococcal conjugate vaccine in March
010. These vaccines, as well as the MenCC vaccine, are available
n a one-dose package demanding a huge space in the cold chain
tructure. The costs of strengthening the cold chain all over the
ountry to allow for the introduction of these new vaccines have
ot been considered in this study, but are certainly important.
urthermore, the immunization schedule adopted by the NIP (at 3,
, and 12 months of age) requires two additional visits to admin-
ster the MenCC vaccine. In this analysis, we assumed that the
accine would be administered simultaneously with other vac-
ines already included in the infant schedule, and so the costs of
hese additional visits were not considered.
Costs of adverse events associated with vaccination were also
ot considered because they are rare.
Vaccination programs may provide indirect effects. Individuals
n the target population who are not vaccinated and the unvacci-
ated contacts of immunized individuals outside the target vacci-
ation cohort (e.g., household relatives of immunized children)
ay receive protection from the disease via the immunization of
thers and the reduced transmission in the community. This phe-
omenon is described by the term herd protection [35]. A decision
tree static model was used in this study, and static models may
underestimate the benefits of the vaccination program by failing
to consider its indirect effects (herd protection), resulting in higher
values of ICERs. Large-scale immunization programs in Canada,
Spain, and the UK evidenced strong herd protection effects asso-
ciated with MenCC vaccine [15–17]. Only one study, however, used
a dynamic model to evaluate cost-effectiveness of an infant me-
ningococcal vaccination program because of the difficulty of de-
veloping the model and its parameterization [44,]. Moreover, herd
protection was observed in countries where catch-up vaccination
was extended to adolescents and young adults. In Brazil, consid-
ering the local MD epidemiology and the vaccine’s availability,
MenCC vaccine is routinely administered only to children younger
than 2 years old.
The cost-effectiveness of any vaccination program will be
greatly influenced by the choice of the alternative program(s) be-
ing evaluated. Failure to recognize the inefficiency of a comparatorstrategy may lead to inaccurate and overly optimistic estimates of
cost-effectiveness [35]. In our cost-effectiveness analysis, we com-
pared the new strategy with the existing program (vaccination of
high-risk population), and the costs and benefits of this option
were explicitly calculated. The choice of the comparison program
was based on local MD epidemiology, with the majority of cases
occurring in the first year of life.
The most important factors that affected the ICER in the sen-
sitivity analysis were estimates of the vaccine protection in the
first and second years, case fatality and incidence rates of MD, and
vaccine cost. The epidemiological estimates are heavily depen-
dent on the pathogen and population characteristics and may
change suddenly and unpredictably. Vaccine prices always affect
ICERs of immunization programs in developing countries. There is
great potential for change in the vaccine’s price, depending on
general economic and political factors and scientific and techno-
logical policies. In 2007 and 2008, the price paid by the Brazilian
NIP for the MenCC vaccine ranged from R$26 to R$30 per dose
which is slightly below that used in this study (R$32.43). Negotia-
tions between the Brazilian Ministry of Health and the manufac-
turer for the introduction of the vaccine into the NIP set its price at
R$19 per dose. At this price, the ICER of the universal vaccination
program in this study, all other things equal, will be R$12,844 per
LYS, in the society’s perspective, very close to the threshold of a
very cost-effective intervention, according to WHO criteria of less
than one GDP per capita per DALY avoided (Fig. 3) [33]. This ICER of
R$12,844 per LYS for the MenCC universal vaccination program is
similar to those found in studies of vaccines recently incorporated
into the routine of the NIP such as rotavirus (R$1,028) [45], pneu-
mococcus (R$22,066) 46, and a vaccine against varicella, not yet
incorporated (R$14,749) [47].
The budgetary impact of incorporating the MenCC vaccine im-
mediately after the introduction of the pneumococcal conjugate
vaccine is very important when considering the values of the 2009
Brazilian NIP budget. The Ministry of Health invested R$552 mil-
lion to buy the 10-valent pneumococcal and the MenCC vaccines
in 2010, representing 66.2% of the 2009 NIP budget (R$833.5 mil-
lion) to carry out all immunizations for the whole Brazilian popu-
lation. Introducing two new vaccines into the NIP in such a short
time is a challenge and will require significant additional invest-
ments in health-care personnel, training, and cold chain infra-
structure.
Acknowledgments
The authors thank Professors Jorge Padovan and Marcos Amaku
for assistance in performing the probabilistic sensitivity analysis.
Source of financial support: This study is part of a project to
evaluate the cost-effectiveness of introducing new vaccines into the
Brazilian National Immunization Program, supported by the Ministry
of Health of Brazil and Conselho Nacional de Desenvolvimento
Científico e Tecnológico (CNPq). The authors are researchers of the
Instituto para Avaliação de Tecnologia em Saúde, IATS/CNPq.
R E F E R E N C E S
[1] de Moraes JC, Barata RB. [Meningococcal disease in Sao Paulo, Brazil,
in the 20th century: epidemiological characteristics]. Cad Saude
Publica 2005;21:1458–71.
[2] Puricelli RC, Kupek E, Westrupp MH. Three decades of meningococcal
disease in the state of Santa Catarina, Brazil. Braz J Infect Dis 2004;8:
241–8.
[3] Safadi MA, Cintra OA. Epidemiology of meningococcal disease in Latin
America: current situation and opportunities for prevention. Neurol
Res 2010;32:263–71.[4] Ministério da Saúde/Secretaria de Vigilância em Saúde / Departamento
de Vigilância Epidemiológica. Doença Meningocócica no Brasil. Nota
1027V A L U E I N H E A L T H 1 4 ( 2 0 1 1 ) 1 0 1 9 – 1 0 2 7Técnica 15.03.2010. Available from: http://portal.saude.gov.br/portal/
arquivos/pdf/nt_meningite_brasil15_03.pdf. [Accessed in June 3, 2010].
[5] Organización Panamericana de la Salud. Informe Regional de
SIREVA II, 2007. Datos por país y por grupos de edad sobre las
características de los aislamientos de Streptococcus pneumoniae,
Haemophilus influenzae y Neisseria meningitidis en procesos
envasores. Documentos Técnicos. Tecnologia Esenciales de Salud.
THR/HT - 2008/003.
[6] Edmond K, Clark A, Korczak VS, et al. Global and regional risk of
disabling sequelae from bacterial meningitis: a systematic review and
meta-analysis. Lancet Infect Dis 2010;10:317–28.
[7] Khatami A, Pollard AJ. The epidemiology of meningococcal disease
and the impact of vaccines. Expert Rev Vaccines 2010;9:285–98.
[8] Ministério da Saúde. Programa Nacional de Imunizações. Manual dos
Centros de Referência para Imunobiológicos Especiais (CRIEs). 3a ed.
Brasilia, DF. 2006. Available at http://portal.saude.gov.br/portal/
arquivos/pdf/livro_cries_3ed.pdf. [Accessed 12 July 2010].
[9] Ministério da Saúde.Secretaria de Ciência, Tecnologia e Insumos
Estratégicos. Departamento de Ciência e Tecnologia. Diretrizes
Metodológicas. Estudos de Avaliação Econômica de Tecnologias em
Saúde. Brasília, DF. 2009.
[10] Gray AM CP, Wolstenholme JL, Wordsworth S. Applied methods of
cost-effectiveness analysis in health care. New York: Oxford
University Press; 2011.
[11] Whang W, Sisk JE, Heitjan DF, et al. Probabilistic sensitivity analysis in
cost-effectiveness. An application from a study of vaccination against
pneumococcal bacteremia in the elderly. Int J Technol Assess Health
Care 1999;15:563–72.
[12] Luna EJ, Veras MA, Flannery B, et al. Household survey of hepatitis B
vaccine coverage among Brazilian children. Vaccine 2009;27:5326–31.
[13] Trotter CL, Andrews NJ, Kaczmarski EB, et al. Effectiveness of
meningococcal serogroup C conjugate vaccine 4 years after
introduction. Lancet 2004;364:365–7.
[14] Larrauri A, Cano R, Garcia M, et al. Impact and effectiveness of
meningococcal C conjugate vaccine following its introduction in
Spain. Vaccine 2005;23:4097–100.
[15] Bettinger JA, Scheifele DW, Le Saux N, et al. The impact of childhood
meningococcal serogroup C conjugate vaccine programs in Canada.
Pediatr Infect Dis J 2009;28:220–4.
[16] Campbell H, Borrow R, Salisbury D, et al. Meningococcal C conjugate
vaccine: the experience in England and Wales. Vaccine 2009;27 Suppl
2:B20-9.
[17] Martinez AI, Dominguez A, Oviedo M, et al. Changes in the evolution
of meningococcal disease, 2001-2008, Catalonia (Spain). Vaccine 2009;
27:3496–8.
[18] Podewils LJ, Antil L, Hummelman E, et al. Projected cost-effectiveness
of rotavirus vaccination for children in Asia. J Infect Dis 2005;192
Suppl 1:S133-45.
[19] WHO. Projected vaccine wastage. Available from: http://www.who.int/
immunization_delivery/systems_policy/logistics_projected_wastage/
en/index.html.[Accessed in June 3, 2010].
[20] Ministério da Saúde. Sistema de Informação sobre Agravos de
Notificação (SINAN). Available from: http://dtr2004.saude.
gov.br/sinanweb/tabnet/dh?sinan/meningite/bases/meninbr.def.
[Accessed July 20, 2007] [database on the Internet].
[21] Divisão de Doenças Respiratórias, Centro de Vigilância Epidemiológica,
Secretaria de Estado da Saúde de São Paulo. Meningites.; Available from:
http://www.cve.saude.sp.gov.br/htm/resp/meni0409_cobetiol.htm.
[Accessed in June 3, 2010].
[22] Ministério da Saúde. Indicadores e Dados Básicos - Brasil - 2008. IDB-
Brasil-2008. Available from: http://tabnet.datasus.gov.br/cgi/idb2008/
matriz.htm.[Accessed in June 3, 10].
[23] Stella-Silva N, Oliveira SA, Marzochi KB. [Meningococcal disease:
comparison between clinical forms]. Rev Soc Bras Med Trop 2007;40:
304–10.
[24] Anjos LP, Queiros F, Pereira MC, et al. [Audiologic late prognosis due to
meningitis in children]. Arq Neuropsiquiatr 2004;62:635–40.
[25] Casella EB, Cypel S, Osmo AA, et al. Sequelae from meningococcal
meningitis in children: a critical analysis of dexamethasone therapy
Arq Neuropsiquiatr. 2004;62:421–8.[26] Couto MI, Monteiro SR, Lichtig I, et al. [Audiological assessment and
follow-up after bacterial meningitis]. Arq Neuropsiquiatr 1999;57:808–12.
[27] IBGE (Instituto Brasileiro de Geografia e Estatística). Pesquisa Nacional
por Amostra de Domicílios (PNAD), 2003. Available from: http://www.
ibge.gov.br/home/estatistica/populacao/trabalhoerendimento/
pnad2003/coeficiente_brasil.shtm. Accessed June 3, 2010].
[28] Ministério da Saúde. DATASUS.Sistema de Informação Hospitalar
(SIH/DATASUS). Cd-rom, 2006.
[29] Agência Nacional de Saúde Suplementar (ANS). Sistema de
Informação de Produto (SIP). Available from: http://www.ans.gov.
br/portal/upload/consultas/RN177_anexo_%2006.11.pdf. Accessed
April 15, 2008.
[30] Ministério da Saúde. DATASUS. Sistema de Informação Ambulatorial
(SIA/DATASUS). Available from: http://tabnet.datasus.gov.br/cgi/
deftohtm.exe?sia/cnv/qbuf.def. [Accessed July 25, 2009]. [database on
the Internet].
[31] De Wals P, Erickson L. Economic analysis of the 1992-1993 mass
immunization campaign against serogroup C meningococcal disease
in Quebec. Vaccine 2002;20:2840–4.
[32] De Wals P, Nguyen VH, Erickson LJ, et al. Cost-effectiveness of
immunization strategies for the control of serogroup C meningococcal
disease. Vaccine 2004;22:1233–40.
[33] WHO. The world report 2002 - reducing risks, promoting healthy life.
Chapter 5: Some estrategies to reduce risk. Geneva. WHO, 2002.
[34] Cleemput I, Neyt M, Thiry N, De Laet C, Leys M. Threshold values for
cost-effectiveness in health care. Health Technology Assessment
(HTA). Brussels: Belgian Health Care Knowledge Centre (KCE), 2008.
KCE reports 100C (D/2008/10.273/96).
[35] Kauf TL. Methodological concerns with economic evaluations of
meningococcal vaccines. Pharmacoeconomics 2010;28:449–61.
[36] Slinko VG, Sweeny A. Reduction in invasive meningococcal disease in
Queensland: a success for immunisation. Commun Dis Intell 2007;31:
227–32.
[37] Bovier PA, Wyss K, Au HJ. A cost-effectiveness analysis of vaccination
strategies against N. meningitidis meningitis in sub-Saharan African
countries. Soc Sci Med 1999;48:1205–20.
[38] Divisão de Doenças Respiratórias, Centro de Vigilância Epidemiológica,
Secretaria de Estado da Saúde de São Paulo. Meningites. Available from:
http://www.cve.saude.sp.gov.br/htm/resp/gr_meni1.htm. [Accessed June
3, 2010].
[39] Barroso DE, Silva LA. Neisseria meningitidis: a neglected cause of
infectious haemorrhagic fever in the amazon rainforest. Braz J Infect
Dis 2007;11:598–602.
[40] Barbieri M, Drummond M, Rutten F, et al. What do international
pharmacoeconomic guidelines say about economic data
transferability? Value Health 2010;13:1028–37.
[41] Stouthard MEA E-BM, Bonsel GJ. Methodology: disability weights for
diseases. A mofified protocol and results for a Western European
region. Eur J Public Health 2000;10:24–30.
[42] Welte R, Trotter CL, Edmunds WJ, et al. The role of economic
evaluation in vaccine decision making: focus on meningococcal group
C conjugate vaccine. Pharmacoeconomics 2005;23:855–74.
[43] Riley AW. Evidence that school-age children can self-report on their
health. Ambul Pediatr 2004;4:371–6.
[44] Trotter CL, Edmunds WJ, Ramsay ME, et al. Modeling future changes
to the meningococcal serogroup C conjugate (MCC) vaccine program
in England and Wales. Hum Vaccin 2006;2:68–73.
[45] de Soarez PC, Valentim J, Sartori AM, et al. Cost-effectiveness analysis
of routine rotavirus vaccination in Brazil. Rev Panam Salud Publica
2008;23:221–30.
[46] Sartori AM, de Soarez PC, Novaes HM. Cost-effectiveness of
introducing the 10-valent pneumococcal conjugate vaccine into the
universal immunisation of infants in Brazil. J Epidemiol Community
Health 2010.
[47] Valentim J, Sartori AM, de Soarez PC, et al. Cost-effectiveness analysis
of universal childhood vaccination against varicella in Brazil. Vaccine
2008;26:6281–91.
